Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D58JRA
|
|||
| Drug Name |
ABP 938
|
|||
| Synonyms |
aflibercept biosimilar
Click to Show/Hide
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Neovascular age-related macular degeneration [ICD-11: 9B78.3Z; ICD-9: 362.5] | Phase 3 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor (VEGFR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04270747) A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea?) in Subjects With Neovascular Age-related Macular Degeneration. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.